Sartorius, a leading international partner of biopharmaceutical research and industry, has signed an agreement to acquire a majority interest in the Israeli cell culture media developer and manufacturer Biological Industries.
For approximately $49,79 (€45 million) million in cash, Sartorius acquired just over 50% of the company’s shares from its current owners, Kibbutz Beit Haemek and Fortissimo. In addition, an option to acquire a further 20% of the shares within three years was agreed upon. The transaction is subject to customary closing conditions and is expected to close in mid-December.
“By acquiring a majority stake in Biological Industries, we are significantly expanding our range of cell culture media and complementing our product portfolio for customers in the dynamically growing market for advanced therapies,” said Joachim Kreuzburg, Chairman of the Executive Board of the Sartorius Group.
Stay up to date on the latest biotech advances with Born2Invest. Our companion app includes news updates of economic headlines from finance and investing to cannabis, Africa, fintech, and more.
Biological Industries focuses on cell culture media, in particular for cell and gene therapy, regenerative medicine and other advanced therapies. Founded in 1981, the company currently employs approximately 130 people, mainly at its headquarters, research and development and production site near Haifa, Israel, and sales offices in the U.S., Europe, and China. Biological Industries is recording significant sales growth and expects sales of around $27,65 million (€25 million) for the current year with a double-digit operating EBITDA margin.
Cell culture media are used in research, clinical development, and manufacturing of biopharmaceuticals as well as in cell and tissue therapy applications. Biological Industries offers complete media solutions with a comprehensive portfolio of clinical-grade media for cell and stem cell cultivation and cryopreservation. These two applications are particularly relevant in both advanced therapy research and clinical development. In addition, Biological Industries offers cell culture reagents as well as classical and serum-free media.
Sartorius at a glance
The Sartorius Group is a leading international partner for biopharmaceutical research and industry. With its innovative laboratory instruments and consumables, the Lab Products & Services division focuses on research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies and academic research institutions.
The Bioprocess Solutions division contributes to the safe and efficient production of biotech drugs and vaccines with a broad product portfolio focusing on disposable solutions. The Group is growing at an average double-digit rate each year and regularly complements its portfolio with acquisitions of complementary technologies.
In fiscal 2018, the company generated sales of around $1,736 billion (€1.57 billion). Currently, more than 8,800 employees work for customers around the globe at the Group’s approximately 60 production and sales locations.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in finanzen.net, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Making Genetics seeks €3 million to conduct a clinical trial in Europe
Making Genetics advances in genetics and epigenetics. The Spanish biotech company seeks $3.6 million (€3 million) to conduct a clinical...
Fez-Meknes: the roadmap for economic recovery is ready
The CRI Fez-Meknes conducted a series of interviews with institutional partners and a survey of economic operators in the region...
Workinvoice and Banca Sella to develop end-to-end digital financial services for SMES
The collaboration between the companies will allow Banca Sella's SME customers to take advantage of the best digital solutions to...
The Viechtach brewery launches a crowdfunding campaign to cope with the health crisis
The Viechtach brewery in the district of Regen is trying to fight the corona crisis with crowdfunding. Owner Markus Grüsser...
The support for medical cannabis is growing in Spain
The percentage of Spanish people who support the use of medical cannabis rises to 90% (from 84% in the previous...
Business6 days ago
Using images in your website: what you need to know
Crypto5 days ago
ETC Group launches first ETP on centrally cleared cryptocurrency Litecoin
Featured4 days ago
Our ‘Chart of the Week’ looks at Bitcoin and the new star of the crypto market – Dogecoin
Business4 days ago
The Dow Jones, CinC & the BGMI 1920 to 2021